Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05656105 · ClinicalTrials.gov registry record · Early Phase 1
Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection
A Early Phase 1 study of SARS CoV-2 Post-Acute Sequelae, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05656105 is a Early Phase 1 study of SARS CoV-2 Post-Acute Sequelae that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05656105, a Early Phase 1 study of SARS CoV-2 Post-Acute Sequelae, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical imaging study will use the small molecule translocator protein (TSPO) ligand, Fluorodeoxyglucose(18F)-labeled DPA-714, to visualize and quantify neuroinflammation in individuals with post-acute sequelae of SARS-CoV-2 (PASC) . The brain uptake of DPA-714 will be contrasted with healthy subjects.
Conditions Studied
Interventions
- DRUG DPA-714 PET/MRI
Study Locations (1)
Alabama
- UAB - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-11-10 |
| Est. Completion | 2028-06-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05656105
The ClinicalTrials.gov registry entry for NCT05656105 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SARS CoV-2 Post-Acute Sequelae appearing as the primary indexed condition, and to 1 intervention - of which DPA-714 PET/MRI is the first listed.
NCT05656105 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT05656105 about?
NCT05656105 is a clinical study titled "Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection". This clinical imaging study will use the small molecule translocator protein (TSPO) ligand, Fluorodeoxyglucose(18F)-labeled DPA-714, to visualize and quantify neuroinflammation in individuals with post-acute sequelae of SARS-CoV-2 (PASC) . The brain uptake of DPA-714 will be contrasted with healthy ...
What is the current status of trial NCT05656105?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2023-11-10. Estimated completion is 2028-06-01.
What conditions does trial NCT05656105 study?
This clinical trial studies the following conditions: SARS CoV-2 Post-Acute Sequelae.
What interventions are being tested in trial NCT05656105?
The interventions under investigation include: DPA-714 PET/MRI (DRUG).
Who is sponsoring clinical trial NCT05656105?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05656105 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.